SCHEMBL23769393

SCHEMBL23769393

CCOC(=O)c1cc(Cc2ccc(N3CC4C(C3)C4(F)F)nc2CC)nn1CC

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.35
KLKB1 P03952 8/20 0.34
TDP1 Q9NUW8 3/20 0.33
RAB9A P51151 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PDE10A Q9Y233 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 1/20 0.32
DGAT2 Q96PD7 1/20 0.31
NPC1 O15118 2/20 0.31
KDM4E B2RXH2 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
KMT2A Q03164 1/20 0.31
CCR4 P51679 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23769415 0.91 KLKB1 (0.39) FAAHKLKB1TDP1RAB9AL3MBTL1
SCHEMBL23768860 0.89 KLKB1 (0.34) KLKB1
SCHEMBL23769529 0.89 KLKB1 (0.33) KLKB1PDE10A
SCHEMBL29906631 0.88 KLKB1 (0.39) FAAHKLKB1TDP1RAB9AL3MBTL1
SCHEMBL23769127 0.88 KLKB1 (0.39) FAAHKLKB1TDP1RAB9AL3MBTL1
SCHEMBL29906612 0.88 KLKB1 (0.34) KLKB1RAB9APDE10ANPC1KDM4E
SCHEMBL23769464 0.83 KLKB1 (0.33) KLKB1L3MBTL1PDE10AKMT2A
SCHEMBL23769707 0.82 FAAH (0.34) FAAHKLKB1TDP1RAB9AL3MBTL1
SCHEMBL23768877 0.81 KLKB1 (0.42) KLKB1NPC1
SCHEMBL23768862 0.79 KLKB1 (0.33) KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 FAAH 162/4885KLKB1 1/4885TDP1 2205/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 FAAH 162/4885KLKB1 1/4885TDP1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.